IN2014CH00139A - - Google Patents

Download PDF

Info

Publication number
IN2014CH00139A
IN2014CH00139A IN139CH2014A IN2014CH00139A IN 2014CH00139 A IN2014CH00139 A IN 2014CH00139A IN 139CH2014 A IN139CH2014 A IN 139CH2014A IN 2014CH00139 A IN2014CH00139 A IN 2014CH00139A
Authority
IN
India
Prior art keywords
combination
bronchodilator
expectorant
antihistamine
nsaid
Prior art date
Application number
Other languages
English (en)
Inventor
Rahul Nayak
Amruth Gowda
Nagaprasad Vishnubhotla
Sivakumaran Meenakshisunderam
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Priority to IN139CH2014 priority Critical patent/IN2014CH00139A/en
Publication of IN2014CH00139A publication Critical patent/IN2014CH00139A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN139CH2014 2014-01-10 2014-01-10 IN2014CH00139A (https=)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN139CH2014 IN2014CH00139A (https=) 2014-01-10 2014-01-10

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN139CH2014 IN2014CH00139A (https=) 2014-01-10 2014-01-10

Publications (1)

Publication Number Publication Date
IN2014CH00139A true IN2014CH00139A (https=) 2015-07-17

Family

ID=54393430

Family Applications (1)

Application Number Title Priority Date Filing Date
IN139CH2014 IN2014CH00139A (https=) 2014-01-10 2014-01-10

Country Status (1)

Country Link
IN (1) IN2014CH00139A (https=)

Similar Documents

Publication Publication Date Title
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
ECSP17084331A (es) Formulaciones farmacéuticas
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
MX2018008021A (es) Metodos y composiciones para el tratamiento de trastornos relacionados con convulsiones.
TN2019000148A1 (en) Pharmaceutical formulations
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
SG11202100369WA (en) Pharmaceutical dosage form which can be administered orally and has modified release
MX384447B (es) Composiciones farmacéuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
HK1245131A1 (zh) 用於治疗炎症性疾病的包含十六酰胺乙醇pea和番茄红素的组合物
IN2013MU03370A (https=)
IN2014CH00139A (https=)
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
PL3300730T3 (pl) Zastosowanie medyczne 5,7-dihydroksy-3-(4-hydroksyfenylo)-4H-1-benzopiran-4-onu w terapii choroby Huntingtona oraz farmaceutycznie akceptowalna postać leku
WO2014184663A3 (en) Orally dispersible drug formulations
IN2013MU02015A (https=)
MX2015009504A (es) Composicion farmaceutica de desloratadina para ser administrada por via oral, para el tratamiento de enfermedades relacionadas con la histamina.
AR099971A1 (es) Forma de dosificación unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolítico que comprende darunavir y ritonavir
HK1243323A1 (zh) 使用赤式羟基安非他酮调节药物血浆水平的方法
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
MY203481A (en) Pharmaceutical compositions comprising meloxicam